GlymaxX®: Elegant Glyco-Engineering to Boost the ADCC Activity of Antibodies
This technology is based on the heterologous, cytosolic expression of a bacterial enzyme that redirects the de-novo fucose synthesis pathway towards a sugar-nucleotide that cannot be metabolized by the cell. The enzyme mediates the secretion of antibodies with minimized fucose content. The resulting modification of the glycostructure of IgG1 antibodies enhances their binding to NK cells and thus the ADCC response in potency assays. Consequently, the potency of the modified antibodies, directed against tumor or infected cells, is substantially increased.
The GlymaxX® technology ...
- ... yields antibodies with a minimized fucose content
- ... increases FcγRIIIa binding
- ... can be applied to new and preexisting producer cell clones
- ... can be engineered in less than 10 weeks
- ... is applicable to different species
- … requires no culture additives
- … may even enhance productivity
- … is free-of-royalties
For detailed information:
Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase.
von Horsten HH, Ogorek C., Blanchard V., Demmler C., Giese C., Winkler K., Kaup M., Berger M., Jordan I., Sandig V.
Glycobiology. 2010 Dec; 20 (12):1607-18. Epub 2010 Jul 15.
PMID: 20639190 [PubMed – indexed for MEDLINE]